- Historical context40th pct
- Persistence4 periods
- Independent evidence1 group
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAdaptive Biotechnologies Corp's latest supported as-filed period reports revenue of $71.6M. Every value below links to its SEC accession and metric lineage.
Unusual transitions and combinations worth inspecting—not forecasts or recommendations.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 0.00% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.65% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -8.94% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 21.53% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 14.67% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 71.82% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 21.5%; Operating margin moved 2048 bp higher; Operating income increased 37.0%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 293.6%; Operating cash flow increased 48.5%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 80.8%; Capex / revenue moved 54 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 24.9%; Inventory / revenue moved 40 bp higher.
2 evidence-backed componentsTotal assets changed +29.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
ADPT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001780664-26-000047SEC ↗4Oct 26, 2026Period Oct 22, 20260001780664-26-000045SEC ↗4Oct 21, 2026Period Oct 19, 20260001780664-26-000043SEC ↗4Oct 16, 2026Period Oct 14, 20260001780664-26-000041SEC ↗4Oct 13, 2026Period Oct 9, 20260001780664-26-000039SEC ↗4Oct 8, 2026Period Oct 6, 20260001780664-26-000037SEC ↗4Oct 8, 2026Period Oct 6, 20260001820885-26-000025SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 29, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |
| Oct 29, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 11,881 | $28 | $335,876 | Form 4 ↗ |
| Oct 29, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $0 | $0 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value -22.04% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 26.77% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 15.54% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Current assets changed +60.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Noncurrent long-term debt changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +96.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed +68.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed +1778 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +37.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001780664-26-000035| RUBINSTEIN JULIEPresident and COO |
| Open Market SaleDirect |
| 11,681 |
| $28 |
| $332,208 |
| Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 200 | $29 | $5,780 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $0 | $0 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 3,000 | $27 | $79,740 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 8,881 | $28 | $244,494 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $0 | $0 | Form 4 ↗ |
| Oct 26, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |
| Oct 26, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 8,503 | $26 | $220,568 | Form 4 ↗ |
| Oct 26, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 3,378 | $26 | $88,841 | Form 4 ↗ |
| Oct 26, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $0 | $0 | Form 4 ↗ |
| Oct 23, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |
| Oct 23, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 4,500 | $25 | $110,250 | Form 4 ↗ |
| Oct 23, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Open Market SaleDirect | 7,381 | $25 | $186,592 | Form 4 ↗ |
| Oct 23, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $0 | $0 | Form 4 ↗ |
| Oct 22, 2026Filed Oct 26, 2026 | RUBINSTEIN JULIEPresident and COO | Option ExerciseDirect | 11,881 | $12 | $144,235 | Form 4 ↗ |